Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma

Ken C. Lo, Changxing Ma, Brian N. Bundy, Scott L. Pomeroy, Charles G. Eberhart, John Kenneth Cowell

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: Tumor risk stratification during diagnosis is paramount for children with medulloblastomas, primarily because very young patients (<3 years) suffer cognitive deficits from radio- and chemotherapy sequelae. Thus, distinguishing tumors that are biologically more aggressive is essential for medulloblastoma management to maximize the delay in radiation treatment without adversely affecting survival outcome. In this context, current strategies for risk assessment, which are based on clinical parameters, remain unsatisfactory. Experimental Design: Array-based comparative genomic hybridization (aCGH) was used to identify chromosomal copy number abnormalities in a cohort of 49 medulloblastoma tumors. Basedon the karyotypes generated from a CGH analysis, each tumorwas scored for copy number abnormalities, and the log-rank test was used to evaluate whether any cytogenetic events were associated with survival. Results: A single copy gain of 1q was shown to be a negative prognostic marker for survival in medulloblastomas with high statistical significance (P < 0.0001, log-rank test). Conclusion: A gain of 1q provides a potential means of predicting overall survival in medulloblastoma.

Original languageEnglish (US)
Pages (from-to)7022-7028
Number of pages7
JournalClinical Cancer Research
Volume13
Issue number23
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Medulloblastoma
Survival
Neoplasms
Comparative Genomic Hybridization
Karyotype
Cytogenetics
Research Design
Radiotherapy
Radiation
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. / Lo, Ken C.; Ma, Changxing; Bundy, Brian N.; Pomeroy, Scott L.; Eberhart, Charles G.; Cowell, John Kenneth.

In: Clinical Cancer Research, Vol. 13, No. 23, 01.12.2007, p. 7022-7028.

Research output: Contribution to journalArticle

Lo, Ken C. ; Ma, Changxing ; Bundy, Brian N. ; Pomeroy, Scott L. ; Eberhart, Charles G. ; Cowell, John Kenneth. / Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 23. pp. 7022-7028.
@article{12e441f6930e45a1afdca81936b62994,
title = "Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma",
abstract = "Purpose: Tumor risk stratification during diagnosis is paramount for children with medulloblastomas, primarily because very young patients (<3 years) suffer cognitive deficits from radio- and chemotherapy sequelae. Thus, distinguishing tumors that are biologically more aggressive is essential for medulloblastoma management to maximize the delay in radiation treatment without adversely affecting survival outcome. In this context, current strategies for risk assessment, which are based on clinical parameters, remain unsatisfactory. Experimental Design: Array-based comparative genomic hybridization (aCGH) was used to identify chromosomal copy number abnormalities in a cohort of 49 medulloblastoma tumors. Basedon the karyotypes generated from a CGH analysis, each tumorwas scored for copy number abnormalities, and the log-rank test was used to evaluate whether any cytogenetic events were associated with survival. Results: A single copy gain of 1q was shown to be a negative prognostic marker for survival in medulloblastomas with high statistical significance (P < 0.0001, log-rank test). Conclusion: A gain of 1q provides a potential means of predicting overall survival in medulloblastoma.",
author = "Lo, {Ken C.} and Changxing Ma and Bundy, {Brian N.} and Pomeroy, {Scott L.} and Eberhart, {Charles G.} and Cowell, {John Kenneth}",
year = "2007",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-07-1420",
language = "English (US)",
volume = "13",
pages = "7022--7028",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma

AU - Lo, Ken C.

AU - Ma, Changxing

AU - Bundy, Brian N.

AU - Pomeroy, Scott L.

AU - Eberhart, Charles G.

AU - Cowell, John Kenneth

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Purpose: Tumor risk stratification during diagnosis is paramount for children with medulloblastomas, primarily because very young patients (<3 years) suffer cognitive deficits from radio- and chemotherapy sequelae. Thus, distinguishing tumors that are biologically more aggressive is essential for medulloblastoma management to maximize the delay in radiation treatment without adversely affecting survival outcome. In this context, current strategies for risk assessment, which are based on clinical parameters, remain unsatisfactory. Experimental Design: Array-based comparative genomic hybridization (aCGH) was used to identify chromosomal copy number abnormalities in a cohort of 49 medulloblastoma tumors. Basedon the karyotypes generated from a CGH analysis, each tumorwas scored for copy number abnormalities, and the log-rank test was used to evaluate whether any cytogenetic events were associated with survival. Results: A single copy gain of 1q was shown to be a negative prognostic marker for survival in medulloblastomas with high statistical significance (P < 0.0001, log-rank test). Conclusion: A gain of 1q provides a potential means of predicting overall survival in medulloblastoma.

AB - Purpose: Tumor risk stratification during diagnosis is paramount for children with medulloblastomas, primarily because very young patients (<3 years) suffer cognitive deficits from radio- and chemotherapy sequelae. Thus, distinguishing tumors that are biologically more aggressive is essential for medulloblastoma management to maximize the delay in radiation treatment without adversely affecting survival outcome. In this context, current strategies for risk assessment, which are based on clinical parameters, remain unsatisfactory. Experimental Design: Array-based comparative genomic hybridization (aCGH) was used to identify chromosomal copy number abnormalities in a cohort of 49 medulloblastoma tumors. Basedon the karyotypes generated from a CGH analysis, each tumorwas scored for copy number abnormalities, and the log-rank test was used to evaluate whether any cytogenetic events were associated with survival. Results: A single copy gain of 1q was shown to be a negative prognostic marker for survival in medulloblastomas with high statistical significance (P < 0.0001, log-rank test). Conclusion: A gain of 1q provides a potential means of predicting overall survival in medulloblastoma.

UR - http://www.scopus.com/inward/record.url?scp=37249090639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249090639&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1420

DO - 10.1158/1078-0432.CCR-07-1420

M3 - Article

VL - 13

SP - 7022

EP - 7028

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -